Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POSIMIR vs ALPHACAINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bupivacaine, the active ingredient in POSIMIR, is an amide-type local anesthetic that blocks voltage-gated sodium channels in nerve cell membranes, inhibiting the generation and conduction of nerve impulses. POSIMIR is a bupivacaine extended-release liposomal formulation designed for sustained release at the surgical site.
ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.
Single-dose administration in adults for local analgesia at the surgical site following bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty (TKA).
Local anesthesia for dental procedures,Local anesthesia for minor surgical procedures,Epidural anesthesia (off-label),Peripheral nerve blocks (off-label)
Posimir (bupivacaine) is administered as a single intra-articular injection into the subacromial space following arthroscopic shoulder surgery. The recommended adult dose is 5 m L (66 mg) of the 1.32% solution.
10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.
Terminal elimination half-life is approximately 27 hours (range 16-38 hours), supporting once-daily dosing in clinical use.
Terminal elimination half-life: 3.5-5.0 hours (prolonged in hepatic impairment; requires dose adjustment in Child-Pugh B or C).
Primarily hepatic via conjugation with glucuronic acid; major metabolite is 4-hydroxybupivacaine. CYP3A4 and CYP1A2 are involved in minor oxidative metabolism.
ALPHACAINE is metabolized primarily by the liver via cytochrome P450 enzymes, specifically CYP3A4 and CYP1A2, to inactive metabolites that are excreted renally.
Primarily hepatic metabolism via CYP3A4 and CYP1A2 to inactive metabolites; <5% excreted unchanged in urine. Biliary/fecal excretion accounts for >90% of total clearance.
Renal: ~60-70% unchanged; Hepatic metabolism: ~20-30% via CYP3A4 and CYP2C9; Fecal: <10%.
Approximately 97% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
~92-95% bound, primarily to albumin and alpha-1-acid glycoprotein.
Volume of distribution is approximately 1.9 L/kg, indicating extensive distribution into tissues.
Vd: 2.5-4.0 L/kg (indicates extensive tissue distribution; large Vd suggests accumulation in peripheral tissues).
Not applicable via oral route; only administered as a local infiltration. Systemic bioavailability after local administration is approximately 100% locally, but systemic levels are low due to slow release from the formulation.
Oral: 65-80% (first-pass effect); IM: 90-100%; IV: 100%.
No dose adjustment is required for mild to moderate renal impairment. Safety and efficacy have not been established in severe renal impairment (GFR <30 m L/min), use with caution.
GFR 30-50 m L/min: reduce dose by 25%; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use.
No dose adjustment is required for mild (Child-Pugh A) hepatic impairment. For moderate (Child-Pugh B) impairment, consider cautious use with monitoring for toxicity. Contraindicated in severe (Child-Pugh C) hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Safety and efficacy in pediatric patients have not been established. No standard dosing guidelines exist.
0.5-1 mg/kg IM or IV every 4-6 hours; maximum 4 mg/kg/day.
No specific dose adjustment is recommended, but elderly patients may have increased sensitivity and reduced clearance. Use with caution, monitoring for cardiac and neurological toxicity.
Initiate at 50% of adult dose; titrate cautiously due to increased sensitivity and risk of adverse effects.
Not approved for use in: obstetrical paravertebral block, epidural or intrathecal administration. Risk of cardiac arrest and death has been reported with bupivacaine use via these routes.
There is no FDA black box warning for ALPHACAINE.
Risk of overdose and toxicity with unintentional intravascular injection or excessive dosing.,Do not use in patients with hypersensitivity to bupivacaine or any amide-type local anesthetic.,Not recommended for patients with severe hepatic impairment.,Safety in pediatric patients not established.,Use with caution in patients with cardiovascular disease, especially those with impaired cardiac conduction.,May cause methemoglobinemia in susceptible patients.,Chondrolysis with intra-articular use (not indicated for such use).
Risk of systemic toxicity if injected intravascularly,Use with caution in patients with hepatic impairment,Use with caution in patients with cardiovascular disease,May cause methemoglobinemia in rare cases,Avoid use in patients with known hypersensitivity to amide-type anesthetics
Hypersensitivity to bupivacaine or any component of the formulation,Obstetrical paravertebral block,Epidural or intrathecal administration
Hypersensitivity to ALPHACAINE or any component of the formulation,Severe hepatic impairment,Severe uncontrolled hypotension,Injection into infected or inflamed areas,History of malignant hyperthermia (relative contraindication)
No known food interactions. Avoid alcohol for 24 hours post-administration to minimize additive CNS depression.
No clinically significant food interactions. Grapefruit juice does not affect clearance. Avoid excessive alcohol intake as it may increase risk of sedation and dizziness.
POSIMIR (bupivacaine) is classified as FDA Pregnancy Category C. Animal studies have shown fetal harm, but adequate human studies are lacking. First trimester: Risk of teratogenicity is unknown; bupivacaine crosses the placenta. Second and third trimesters: Potential for fetal bradycardia, CNS depression, and neurobehavioral effects. Use only if benefit outweighs risk.
FDA Category C. First trimester: Increased risk of spontaneous abortion and congenital anomalies (neural tube defects, cardiac malformations) based on animal studies. Second and third trimesters: Potential for fetal growth restriction, preterm labor, and neurobehavioral alterations. Avoid use unless benefit outweighs risk.
Bupivacaine is excreted in breast milk in small amounts. The milk-to-plasma ratio (M/P) is approximately 0.3. The relative infant dose is estimated to be <2% of maternal weight-adjusted dose. Generally considered compatible with breastfeeding, but caution is advised in infants with impaired hepatic function.
Excreted in human milk; M/P ratio estimated at 0.95. Peak milk concentration occurs 1-2 hours after maternal dose. Limited data suggest low risk to term infants, but caution in preterm or ill infants. American Academy of Pediatrics recommends avoiding breastfeeding within 4 hours of maternal dose.
No specific dose adjustments are recommended for POSIMIR in pregnancy. However, physiological changes (increased plasma volume, altered hepatic metabolism) may affect bupivacaine pharmacokinetics, potentially increasing systemic absorption. Use lowest effective dose and monitor for signs of toxicity.
Increased volume of distribution and enhanced hepatic clearance (CYP3A4 induction) in pregnancy require 30-50% dose escalation. Monitor trough levels to achieve therapeutic range (5-15 mg/L). Postpartum dose should be reduced to pre-pregnancy levels within 72 hours.
POSIMIR (bupivacaine) is a long-acting, non-opioid local analgesic administered via infiltration into the surgical site. Its liposomal bupivacaine formulation provides up to 72 hours of analgesia. Do not use for intra-articular, epidural, or intrathecal administration; risk of chondrolysis and nerve injury. Avoid concomitant use with other local anesthetics. Monitor for signs of systemic toxicity (e.g., CNS excitation, cardiac depression). Not recommended in patients with hepatic impairment or myasthenia gravis.
ALPHACAINE (liposomal bupivacaine) provides extended analgesia up to 72 hours. Do not use with bupivacaine HCl or other local anesthetics as it may disrupt liposomal formulation. Avoid bolus injection; administer by slow infiltration only. Use with caution in hepatic impairment due to decreased clearance. Maximum dose: 266 mg (20 m L of 1.3% solution) in adults.
POSIMIR is a long-acting anesthetic injected at the surgical site to reduce pain for up to 3 days.,Do not drive or operate machinery for at least 48 hours after administration due to potential dizziness or sedation.,Report any signs of allergic reaction: rash, itching, swelling, or difficulty breathing.,Avoid applying heat or ice directly to the injection site unless advised by your surgeon.,You may still feel some sensation; use prescribed rescue analgesics as needed.,Do not use additional numbing creams or sprays near the surgical site.,Contact your doctor if you experience severe headache, blurred vision, or ringing in ears.,If you are pregnant or breastfeeding, discuss risks with your healthcare provider.
You will receive a long-acting local anesthetic that provides pain relief for up to 3 days after surgery.,Do not apply heat or ice packs directly over the injection site for 24 hours.,Report any signs of infection such as redness, swelling, or warmth at the injection site.,Avoid driving or operating machinery for 24 hours if you feel dizzy or drowsy.,Take over-the-counter pain relievers as directed if breakthrough pain occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POSIMIR vs ALPHACAINE, answered by our medical review team.
POSIMIR is a Local Anesthetic that works by Bupivacaine, the active ingredient in POSIMIR, is an amide-type local anesthetic that blocks voltage-gated sodium channels in nerve cell membranes, inhibiting the generation and conduction of nerve impulses. POSIMIR is a bupivacaine extended-release liposomal formulation designed for sustained release at the surgical site.. ALPHACAINE is a Local Anesthetic that works by ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POSIMIR and ALPHACAINE depend on the specific clinical indication. These are both Local Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POSIMIR is: Posimir (bupivacaine) is administered as a single intra-articular injection into the subacromial space following arthroscopic shoulder surgery. The recommended adult dose is 5 m L (66 mg) of the 1.32% solution.. The standard adult dose of ALPHACAINE is: 10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POSIMIR and ALPHACAINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POSIMIR is classified as Category C. POSIMIR (bupivacaine) is classified as FDA Pregnancy Category C. Animal studies have shown fetal harm, but adequate human studies are lacking. First trimester: Risk of teratogenici. ALPHACAINE is classified as Category C. FDA Category C. First trimester: Increased risk of spontaneous abortion and congenital anomalies (neural tube defects, cardiac malformations) based on animal studies. Second and th. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.